DEXONALINE is a medication that belongs to the class of corticosteroid compounds. It is considered an anti-inflammatory agent and an immunosuppressant, making it a suitable option for treating conditions associated with skin diseases, respiratory disorders, arthritis, and certain autoimmune disorders. It is also used to manage symptoms related to chemotherapy, such as nausea and vomiting.

DEXONALINE is characterized by its rapid efficacy and a low incidence of side effects when used under medical supervision.

DEXONALINE solution for injection may be administered by:

Intra muscular injection

Intra-articular injection

Intravenous injection

Intravenous infusion

Epidural/transforaminal infiltration

DEXONALINE is a medication that belongs to the class of corticosteroid compounds. It is considered an anti-inflammatory agent and an immunosuppressant, making it a suitable option for treating conditions associated with skin diseases, respiratory disorders, arthritis, and certain autoimmune disorders. It is also used to manage symptoms related to chemotherapy, such as nausea and vomiting.

DEXONALINE is characterized by its rapid efficacy and a low incidence of side effects when used under medical supervision.

DEXONALINE solution for injection may be administered by:

• Intra muscular injection
• Intra-articular injection
• Intravenous injection
• Intravenous infusion
• Epidural/transforaminal infiltration

Each Ampoule of DEXONALINE 2 mL contains:

Dexamethasone sodium phosphate 8.8mg equiv. to Dexamethasone phosphate 8mg.

3.Indications:

DEXONALINE is used as an initial treatment for acute skin disorders such as:

Erythema on the skin surface resulting from increased blood flow.

Eczema on the skin surface.

Dermatological blisters.

DEXONALINE is used in cases of severe acute asthma attacks.

DEXONALINE is indicated in cases of severe shock leading to acute circulatory failure affecting organs.

DEXONALINE is utilized in the treatment of inflammatory conditions, particularly rheumatoid arthritis and bacterial inflammation of the meninges.

DEXONALINE is considered effective in the treatment of cerebral edema and multiple sclerosis.

DEXONALINE is known for its use in treating certain autoimmune diseases, such as systemic lupus erythematosus.

DEXONALINE is considered an ideal choice for the treatment and prevention of nausea and vomiting following surgery or chemotherapy.

In some cases, related to malignant tumors, DEXONALINE is used as a supportive treatment.

Recent clinical studies have indicated that DEXONALINE is effective in treating COVID-19 in patients experiencing respiratory distress and requiring treatment for hypoxemia.

Pregnancy& breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking DEXONALINE.

DEXONALINE crosses the placenta. During pregnancy, especially in the first three months, the medicine should only be used after careful benefit-risk assessment.

Treatment with DEXONALINE during pregnancy, growth disorders in the unborn child cannot be excluded.

Newborns of mothers who received DEXONALINE close to the end of pregnancy may experience a temporary negative impact on blood glucose levels within the first 24 hours after birth.

Respiratory distress syndrome: The short-term use of antepartum DEXONALINE for the prevention of respiratory distress syndrome, when warranted, does not seem to pose a risk.

Pregnancy Category: C.

DEXONALINE should not be used while breastfeeding because it is excreted in breast milk.

1. The recommended dose of DEXONALINE for severe shock is 1-6 mg/kg intravenously as a single dose or 40 mg as an initial dose, with the dose repeated every 2-6 hours as needed.
2. The recommended dose of DEXONALINE for allergic reactions is 4-8 mg intramuscularly once on the first day of the reaction.
3. The recommended dose of DEXONALINE for rheumatoid arthritis is local injection into the joint or soft tissue, with the injection volume and dose varying based on the size of the joint and tissue (4-0.4 mg). The frequency of injections varies from every 3-5 days to every 2-3 weeks depending on the treatment response.
4. The recommended dose of DEXONALINE for meningitis in children aged 6 weeks and older is 0.15 mg/kg intravenously every 6 hours for days 2 to 4 of antibiotic treatment. It should be administered concurrently with the first dose of the antibiotic or 10-20 minutes prior.
5. The recommended dose of DEXONALINE for cerebral edema is 10 mg as a single intravenous dose, followed by 4 mg intramuscularly every 6 hours until symptoms improve. The dose can be reduced after 2-4 days, and the medication should be discontinued within 5-7 days.
6. The recommended dose of DEXONALINE for multiple sclerosis is a high dose of up to 30 mg for 3-5 days during attacks.
7. The recommended dose of DEXONALINE for immunosuppression and inflammation is 0.5 mg intravenously or intramuscularly, divided into two doses.
8. The recommended dose of DEXONALINE for the treatment and prevention of nausea and vomiting post-surgery or after chemotherapy is 12-20 mg intravenously before chemotherapy, followed by a dose of 8 mg intravenously once or twice daily for 2-4 days. In moderately emetogenic chemotherapy, 8 mg is given intravenously before chemotherapy, followed by a dose of 4 mg intravenously on days 2 and 3. In mildly emetogenic chemotherapy, 4-8 mg is given intravenously before chemotherapy.
9. The recommended dose of DEXONALINE for multiple myeloma is 40 mg intravenously on days 1, 8, 15, and 22, repeated every 4 weeks. When administered with bortezomib, a dose of 20 mg is given on the same day and 20 mg the following day.
10. The recommended dose of DEXONALINE for neonatal respiratory distress syndrome is 1.25 mL (5 mg) administered intramuscularly to the mother every 6-12 hours, preferably applying the treatment between 1-7 days before delivery.